Preeclampsia Diagnostics Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	148 Pages	Fortune Business Insights Pvt. Ltd.	September, 2024	FOB19185537

Best Price Guarantee
Price	from $4,850
Length	148 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	September, 2024
SKU	FOB19185537

Preeclampsia Diagnostics Market

Growth Factors of Preeclampsia Diagnostics Market

The preeclampsia diagnostics market size was valued at USD 1.09 billion in 2023, and the market is now projected to grow from USD 1.11 billion in 2024 to USD 1.36 billion by 2032, exhibiting a CAGR of 2.6% during the forecast period of 2024-2032.

Pandemic has introduced about a surge in preeclampsia diagnostics due to increased pregnancies, current on time abortions due to loss of midwives or healthcare facilities, and high dangers related to the disorder amongst COVID-19 positive pregnant women. The presence of proteinuria in every COVID-19 and preeclampsia sufferers creates a diagnostic mission.

Early detection of hypertension problems at some point of pregnancy has constantly been hard. The growing occurrence of preeclampsia and the need to reduce maternal and neonatal loss of life prices triggered enterprise groups to create a novel diagnostic device for the situation. Using point-of-care checking out to diagnose preeclampsia at an early stage facilitates prevent pointless hospitalization and lower the ailment's associated expenses. To cope with the excessive hazard of preterm delivery, leading competitors are collaborating to provide stepped forward diagnostics in the marketplace.

Preeclampsia is turning into more usual, main to increased focus and government approval of stepped forward testing. The Congo Red Test (CRD) detects misfolded proteins inside the urine of pregnant women who can also expand toxemia. It's a brief test that returns findings in three minutes. Biomarkers which include PIGF and SFLT-I had been recognized as desirable signs for predicting preeclampsia onset.

Comprehensive Analysis of Preeclampsia Diagnostics Market

The market for preeclampsia tests is segmented into blood tests and urine analysis, with blood tests expected to grow at the highest rate due to the increasing incidence of preeclampsia and the advantages of blood tests in detecting biomarkers. Urine analysis is expected to expand at a substantial CAGR due to its accessibility, convenience, and non-invasive nature. The consumables segment is expected to grow at the highest CAGR due to the rising number of pregnant women suffering from preeclampsia and the adoption of biomarker diagnosis. The instruments segment is expected to grow due to the increasing hypertensive pregnancy disorder population and the need for urological disease diagnosis centres. The end-user segment includes hospitals, specialty clinics, and diagnostic centres.

The North America region lead the preeclampsia diagnostics market share by benefitting a market size of USD 0.41 billion in 2023 due to increasing acceptance of technologically improved goods, increased awareness of illness severity, and large healthcare spending. The preeclampsia diagnostics market growth is expected to rise as more modern technologies become available.

F. Hoffmann-La Roche Ltd., PerkinElmer Inc., and DRG INSTRUMENTS GMBH are the leading players in the preeclampsia diagnostics market, focusing on research and development to launch cost-effective, advanced diagnostic kits. Other players include Thermo Fisher Scientific Inc., Diabetomics, Metabolomic Diagnostics Ltd., Sera Prognostics, Siemens Healthineers AG, and Bayer AG. These companies are continuously focusing on strategic tendencies, new product launches, distribution network improvements, and partnerships.

In January 2024, LabCorp launched a U.S. FDA-accredited blood check to diagnose and determine intense preeclampsia in pregnant ladies.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Unit Value (USD Billion)

Growth Rate CAGR of 2.6% from 2024-2032

Segmentation By Test Type

- Blood Tests

- Urine Analysis

By Product

- Instruments

- Consumables

By End-user

- Hospitals

- Specialty Clinics

- Diagnostic Centers

- Others

By Geography

- North America (By Test Type, By Product, By End-user, and By Country)

U.S. (By Product)
Canada (By Product)

- Europe (By Test Type, By Product, By End-user, and By Country/Sub-region)

U.K. (By Product)
Germany (By Product)
France (By Product)
Italy (By Product)
Spain (By Product)
Scandinavia (By Product)
Rest of Europe (By Product)

- Asia Pacific (By Test Type, By Product, By End-user, and By Country/Sub-region)

Japan (By Product)
China (By Product)
India (By Product)
Australia (By Product)
Southeast Asia (By Product)
Rest of Asia Pacific (By Product)

- Latin America (By Test Type, By Product, By End-user, and By Country/Sub-region)

Brazil (By Product)
Mexico (By Product)
Rest of Latin America (By Product)

- Middle East & Africa (By Test Type, By Product, By End-user, and By Country/Sub-region)

GCC (By Product)
South Africa (By Product)

- Rest of Middle East & Africa (By Product)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Prevalence of Preeclampsia, Key Countries/Regions, 2022/2023; 4.2. Technological Advancements in Preeclampsia Diagnostics; 4.3. New Product Launch, By Key Players; 4.4. Key Industry Developments – Partnerships, Mergers, and Acquisitions; 4.5. Impact of COVID-19 on the Global Preeclampsia Diagnostics Market
5. Global Preeclampsia Diagnostics Market Analysis, Insights and Forecast, 2019-2032: 5.1. Market Analysis, Insights and Forecast – By Test Type; 5.1.1. Blood Tests; 5.1.2. Urine Analysis; 5.2. Market Analysis, Insights and Forecast – By Product; 5.2.1. Instruments; 5.2.2. Consumables; 5.3. Market Analysis, Insights and Forecast – By End-user; 5.3.1. Hospitals; 5.3.2. Specialty Clinics; 5.3.3. Diagnostic Centers; 5.3.4. Others; 5.4. Market Analysis, Insights and Forecast – By Region; 5.4.1. North America; 5.4.2. Europe; 5.4.3. Asia Pacific; 5.4.4. Latin America; 5.4.5. Middle East & Africa
6. North America Preeclampsia Diagnostics Market Analysis, Insights and Forecast, 2019-2032: 6.1. Market Analysis, Insights and Forecast – By Test Type; 6.1.1. Blood Tests; 6.1.2. Urine Analysis; 6.2. Market Analysis, Insights and Forecast – By Product; 6.2.1. Instruments; 6.2.2. Consumables; 6.3. Market Analysis, Insights and Forecast – By End-user; 6.3.1. Hospitals; 6.3.2. Specialty Clinics; 6.3.3. Diagnostic Centers; 6.3.4. Others; 6.4. Market Analysis, Insights and Forecast – By Country; 6.4.1. U.S.; 6.4.1.1. By Product; 6.4.2. Canada; 6.4.2.1. By Product
7. Europe Preeclampsia Diagnostics Market Analysis, Insights and Forecast, 2019-2032: 7.1. Market Analysis, Insights and Forecast – By Test Type; 7.1.1. Blood Tests; 7.1.2. Urine Analysis; 7.2. Market Analysis, Insights and Forecast – By Product; 7.2.1. Instruments; 7.2.2. Consumables; 7.3. Market Analysis, Insights and Forecast – By End-user; 7.3.1. Hospitals; 7.3.2. Specialty Clinics; 7.3.3. Diagnostic Centers; 7.3.4. Others; 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 7.4.1. Germany; 7.4.1.1. By Product; 7.4.2. U.K.; 7.4.2.1. By Product; 7.4.3. France; 7.4.3.1. By Product; 7.4.4. Italy; 7.4.4.1. By Product; 7.4.5. Spain; 7.4.5.1. By Product; 7.4.6. Scandinavia; 7.4.6.1. By Product; 7.4.7. Rest of Europe; 7.4.7.1. By Product
8. Asia Pacific Preeclampsia Diagnostics Market Analysis, Insights and Forecast, 2019-2032: 8.1. Market Analysis, Insights and Forecast – By Test Type; 8.1.1. Blood Tests; 8.1.2. Urine Analysis; 8.2. Market Analysis, Insights and Forecast – By Product; 8.2.1. Instruments; 8.2.2. Consumables; 8.3. Market Analysis, Insights and Forecast – By End-user; 8.3.1. Hospitals; 8.3.2. Specialty Clinics; 8.3.3. Diagnostic Centers; 8.3.4. Others; 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 8.4.1. Japan; 8.4.1.1. By Product; 8.4.2. China; 8.4.2.1. By Product; 8.4.3. India; 8.4.3.1. By Product; 8.4.4. Australia; 8.4.4.1. By Product; 8.4.5. Southeast Asia; 8.4.5.1. By Product; 8.4.6. Rest of Asia Pacific; 8.4.6.1. By Product
9. Latin America Preeclampsia Diagnostics Market Analysis, Insights and Forecast, 2019-2032: 9.1. Market Analysis, Insights and Forecast – By Test Type; 9.1.1. Blood Tests; 9.1.2. Urine Analysis; 9.2. Market Analysis, Insights and Forecast – By Product; 9.2.1. Instruments; 9.2.2. Consumables; 9.3. Market Analysis, Insights and Forecast – By End-user; 9.3.1. Hospitals; 9.3.2. Specialty Clinics; 9.3.3. Diagnostic Centers; 9.3.4. Others; 9.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 9.4.1. Brazil; 9.4.1.1. By Product; 9.4.2. Mexico; 9.4.2.1. By Product; 9.4.3. Rest of Latin America; 9.4.3.1. By Product
10. Middle East & Africa Preeclampsia Diagnostics Market Analysis, Insights and Forecast, 2019-2032: 10.1. Market Analysis, Insights and Forecast – By Test Type; 10.1.1. Blood Tests; 10.1.2. Urine Analysis; 10.2. Market Analysis, Insights and Forecast – By Product; 10.2.1. Instruments; 10.2.2. Consumables; 10.3. Market Analysis, Insights and Forecast – By End-user; 10.3.1. Hospitals; 10.3.2. Specialty Clinics; 10.3.3. Diagnostic Centers; 10.3.4. Others; 10.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 10.4.1. GCC; 10.4.1.1. By Product; 10.4.2. South Africa; 10.4.2.1. By Product; 10.4.3. Rest of Middle East & Africa; 10.4.3.1. By Product
11. Competitive Analysis: 11.1. Global Market Share Analysis (2023); 11.2. Company Profiles; 11.2.1. F. Hoffmann-La Roche Ltd; 11.2.1.1. Overview; 11.2.1.2. Products & Services; 11.2.1.3. SWOT Analysis; 11.2.1.4. Recent Developments; 11.2.1.5. Strategies; 11.2.1.6. Financials (Based on Availability); 11.2.2. PerkinElmer Inc.; 11.2.2.1. Overview; 11.2.2.2. Products & Services; 11.2.2.3. SWOT Analysis; 11.2.2.4. Recent Developments; 11.2.2.5. Strategies; 11.2.2.6. Financials (Based on Availability); 11.2.3. DRG INSTRUMENTS GMBH; 11.2.3.1. Overview; 11.2.3.2. Products & Services; 11.2.3.3. SWOT Analysis; 11.2.3.4. Recent Developments; 11.2.3.5. Strategies; 11.2.3.6. Financials (Based on Availability); 11.2.4. Thermo Fisher Scientific Inc.; 11.2.4.1. Overview; 11.2.4.2. Products & Services; 11.2.4.3. SWOT Analysis; 11.2.4.4. Recent Developments; 11.2.4.5. Strategies; 11.2.4.6. Financials (Based on Availability); 11.2.5. Diabetomics, Inc.; 11.2.5.1. Overview; 11.2.5.2. Products & Services; 11.2.5.3. SWOT Analysis; 11.2.5.4. Recent Developments; 11.2.5.5. Strategies; 11.2.5.6. Financials (Based on Availability); 11.2.6. Metabolomic Diagnostics Ltd.; 11.2.6.1. Overview; 11.2.6.2. Products & Services; 11.2.6.3. SWOT Analysis; 11.2.6.4. Recent Developments; 11.2.6.5. Strategies; 11.2.6.6. Financials (Based on Availability); 11.2.7. Sera Prognostics; 11.2.7.1. Overview; 11.2.7.2. Products & Services; 11.2.7.3. SWOT Analysis; 11.2.7.4. Recent Developments; 11.2.7.5. Strategies; 11.2.7.6. Financials (Based on Availability); 11.2.8. Siemens Healthineers AG; 11.2.8.1. Overview; 11.2.8.2. Products & Services; 11.2.8.3. SWOT Analysis; 11.2.8.4. Recent Developments; 11.2.8.5. Strategies; 11.2.8.6. Financials (Based on Availability)